BioCentury
ARTICLE | Clinical News

NP137: Ph I started

March 29, 2017 12:55 AM UTC

Netris began an open-label, 2-part, French Phase I trial to evaluate IV NP137 given every other week in about 44 patients. The dose-escalation part 1 will evaluate 1, 2, 4, 6, 9, 14 and 20 mg/kg doses...

BCIQ Company Profiles

Netris Pharma S.A.S.

BCIQ Target Profiles

Netrin 1 (NTN1)